Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

Regeneron (REGN 1.33%) has been ... No doubt the drugmaker owes this performance in part to its coronavirus-related work. However, ... 1 Dividend Stock Down 30% to Buy and Hold for the Next Decade.

No doubt the drugmaker owes this performance in part to its coronavirus-r. Skip to main content. Nasdaq+. Weekly ... Is Regeneron Stock a Buy Now? March 11, 2022 — 11:30 am EST.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

REGEN-COV sales, as discussed, will fall from $5.8bn in FY21 to just $681.2m in FY22, but the performance of both Libtayo ... IMO LT investors should continue to buy REGN’s stock every 3-months.

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago ...

And that's why I'm taking a close look at Regeneron Pharmaceuticals (REGN-0.75%), which is trading at about $830 after touching a recent peak of $847.50. Could this big biotech company be next to ...